Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?

Experimental dermatology - 1 Dec 2011

Passeron Thierry, Lacour Jean-Philippe, Allegra Maryline, Ségalen Coralie, Deville Anne, Thyss Antoine, Giacchero Damien, Ortonne Jean-Paul, Bertolotto Corine, Ballotti Robert, Bahadoran Philippe

Abstract excerpt

Selection for targeted therapies in melanoma is currently based on the search for mutations in selected genes. We aimed at evaluating the interest of signalling and chemosensitivity studies in addition to genotyping for assessing the best suitable treatment in an individual patient. We extracted genomic DNA and melanoma cells from tumor tissue of a skin metastasis of a 17-year-old woman with stage IV melanoma...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzenesulfonates
Share to Butadienes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dacarbazine

Share to Niacinamide

Share to Nitriles

Share to Organophosphorus Compounds

Share to Phenylurea Compounds

Share to Sorafenib

Source

Identifiers

PMID: 22092579
DOI: 10.1111/j.1600-0625.2011.01385.x

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Signalling and chemosensitivity assays in melanoma: is mutated status a prerequisite for targeted therapy?PMID 22092579Read ↗

Potential Biomarkers of Skin Melanoma Resistance to Targeted Therapy—Present State and PerspectivesSemantic proximity Read ↗

Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures.Semantic proximity Read ↗

The Future of Molecular Analysis in Melanoma: Diagnostics to Direct Molecularly Targeted Therapy.Semantic proximity Read ↗

Refining Targeted Therapy Opportunities for BRAF-Mutant Melanoma.Semantic proximity Read ↗

BRAF in early stage melanoma: rationale for testing and treatment?Semantic proximity Read ↗

Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.Semantic proximity Read ↗

Molecular testing in malignant melanoma.Semantic proximity Read ↗

A B-Raf V600E gene signature for melanoma predicts prognosis and reveals sensitivity to targeted therapies.Semantic proximity Read ↗

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance.Semantic proximity Read ↗

[Therapeutic approaches in Melanoma - a paradigm for personalized medicine].Semantic proximity Read ↗

[Molecular alterations in melanoma and targeted therapies].Semantic proximity Read ↗

Genetic Layout of Melanoma Lesions Is Associated with BRAF/MEK-Targeted Therapy Resistance and Transcriptional Profiles.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.